Arthritis Juvenile Rheumatoid

• EMA withdrawal · 2021-01-29
  EMA Withdrawn: Halimatoz (adalimumab) — Sandoz GmbH

  The EMA withdrew Halimatoz (adalimumab) supplied by Sandoz GmbH from the market.

• EMA withdrawal · 2020-03-25
  EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH

  EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.

• CLINICAL_TRIALS trial_result · 2015-11-11
  Clinical Trial Update: A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects [Phase 4]

  Phase 4 study evaluating the effects of celecoxib versus naproxen on blood pressure in pediatric arthritis patients has completed with resul…

• CLINICAL_TRIALS trial_result · 2013-07-19
  Clinical Trial Update: Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

  A naturalistic safety registry study on celecoxib (Celebrex) and NSAIDs in juvenile arthritis has been terminated with results posted in 201…